The potential role of n-3 fatty acids and their lipid mediators on asthmatic airway inflammation

Front Immunol. 2024 Dec 10:15:1488570. doi: 10.3389/fimmu.2024.1488570. eCollection 2024.

Abstract

Asthma, is a common, significant and diverse condition marked by persistent airway inflammation, with a major impact on human health worldwide. The predisposing factors for asthma are complex and widespread. The beneficial effects of omega-3 (n-3) polyunsaturated fatty acids (PUFAs) in asthma have increasingly attracted attention recently. In asthma therapy, n-3 PUFAs may reduce asthma risk by controlling on levels of inflammatory cytokines and regulating recruitment of inflammatory cells in asthma. The specialized pro-resolving mediators (SPMs) derived from n-3 PUFAs, including the E- and D-series resolvins, protectins, and maresins, were discovered in inflammatory exudates and their biosynthesis by lipoxygenase mediated pathways elucidated., SPMs alleviated T-helper (Th)1/Th17 and type 2 cytokine immune imbalance, and regulated macrophage polarization and recruitment of inflammatory cells in asthma via specific receptors such as formyl peptide receptor 2 (ALX/FPR2) and G protein-coupled receptor 32. In conclusion, the further study of n-3 PUFAs and their derived SPMs may lead to novel anti-inflammatory asthma treatments.

Keywords: asthma; inflammation; maresin; n-3 fatty acid; protectin; resolvin.

Publication types

  • Review

MeSH terms

  • Animals
  • Asthma* / drug therapy
  • Asthma* / immunology
  • Asthma* / metabolism
  • Cytokines / metabolism
  • Fatty Acids, Omega-3* / therapeutic use
  • Humans
  • Inflammation / drug therapy
  • Inflammation / immunology
  • Inflammation / metabolism
  • Inflammation Mediators* / metabolism

Substances

  • Fatty Acids, Omega-3
  • Inflammation Mediators
  • Cytokines

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Jilin Provincial Science and Technology Agency (YDZJ202201ZYTS628, recipient: Wei-Yu Zhang).